Phase I/II study of the adjunctive use of nilotinib in patients undergoing reduced intensity allogeneic transplantation for imatinib resistant or intolerant chronic myeloid leukaemia.
Phase of Trial: Phase I/II
Latest Information Update: 16 Mar 2016
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- Acronyms TRICE
- 29 Oct 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 18 Oct 2008 New trial record.